Lisa Butterfield, PhD

Bio:

I am a Consultant in Immuno-Oncology and a Scientific Advisory Board member (including the SU2C SAC). My career has been focused on cancer vaccines, immune profiling, biomarker development and cellular therapies for solid tumors. I was recently a Distinguished Scientist at Merck in Discovery Oncology in South San Francisco, and previously, the Vice President, Research and Development at the Parker Institute for Cancer Immunotherapy, as well as an Adjunct Professor of Microbiology and Immunology, University California San Francisco. I have also been a tenured Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh and the Director of the Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory.

I earned a PhD in Biology from UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy also at UCLA. I was the first female President of the Society of Immunotherapy of Cancer (SITC) and a member of the SITC Executive Committee. I co-lead the SITC Women’s Leadership Institute (since 2018). I also previously led the Immunology Reference Lab for the ECOG-ACRIN NCI cooperative group and have collaborated on biomarker studies in many clinical trials. I have published over 200 peer-reviewed manuscripts, reviews and book chapters, led teams of up to 20 members and mentored over 20 students and postdocs. I chaired the FDA Cell, Tissue and Gene Therapy Advisory Committee, and am a co-Editor of the SITC textbook “Cancer Immunotherapy: Principles and Practice” 1st and 2nd editions. I have consulted for over 45 companies and served on many SABs.